Generics, Others Back Impax Against FTC In 5th Circ.

Law360 (October 11, 2019, 8:19 PM EDT) -- A trade group for the generic pharmaceutical industry, along with others, threw support Thursday behind Impax Laboratories LLC's Fifth Circuit appeal seeking a reversal of a Federal Trade Commission decision in a generic delay case, arguing the agency got its analysis all wrong.

The case targets a deal between Impax and Endo Pharmaceuticals Inc. that allegedly delayed the release of a generic version of opioid pain medication Opana ER. It is the FTC’s first fully litigated challenge to a settlement between branded and generic drug makers since the Supreme Court’s landmark 2013 decision in Actavis, in which justices found such settlements...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS